Karen Knudsen, CEO of Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn:
“Provocative new data suggest that patients with high tumor volume going into CAR T are more likely to experience serious toxicity (inc. non-relapse mortality). If we can identify high-risk patients early, we can intervene early, and keep patients safer without compromising outcomes.
This is exactly the kind of science that will be key for continuing to advance immunotherapy cancer cures and matching the right patient to the right cancer treatment, the first time. Data to build on!”
More posts featuring Karen Knudsen.